[HTML][HTML] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

H Ahmadzadehfar, E Eppard, S Kürpig, R Fimmers… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells
and strongly up-regulated in prostate cancer (PC), making it an optimal target for the …

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

H Ahmadzadehfar, K Rahbar, S Kürpig, M Bögemann… - EJNMMI research, 2015 - Springer
Background Radioligand therapy (RLT) with 177 Lu-DKFZ-617 PSMA (Lu-PSMA)(prostate-
specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We …

Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis

K Rahbar, M Schmidt, A Heinzel, E Eppard… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true
theranostic concept for diagnosis and therapy in patients with relapsed or metastatic …

Determination of split renal function using dynamic CT-angiography: preliminary results

A Helck, U Schönermarck, A Habicht… - PloS one, 2014 - journals.plos.org
Objectives To determine the feasibility of a dynamic CT angiography-protocol with regard to
simultaneous assessment of renal anatomy and function. Methods 7 healthy potential kidney …

[18F]-PSMA-1007-PET for evaluation of kidney function

P Rassek, M Schäfers, K Rahbar… - Nuklearmedizin …, 2023 - thieme-connect.com
Purpose Prostate-specific membrane antigen (PSMA) is present in the proximal tubule cells
of the kidneys. This results in high renal tracer uptake in PSMA-PET, which may contain …

Radiation exposure of patients undergoing nuclear medicine procedures in Germany between 1996 and 2000

M Hacker, P Schnell-Inderst, D Nosske… - Nuklearmedizin …, 2005 - thieme-connect.com
The aim of this study was to estimate both the frequency and effective dose of nuclear
medicine procedures performed in Germany between 1996 and 2000 for different …

Residual kidney function after donor nephrectomy

N Hamscho, A Wilhelm, N Döbert… - Nuklearmedizin …, 2005 - thieme-connect.com
Aim: We evaluated the long-term residual renal function after donor nephrectomy using 99m
Tc-mercaptoacetyltriglycin (MAG3)-clearance. Donors, methods: Altogether 49 kidney …

Роль методов ядерной медицины в определении объема хирургического лечения больных раком почки. Литературный обзор

ВА Башмаков - Вестник Российского научного центра …, 2010 - cyberleninka.ru
В работе описаны особенности обследования и лечения пациентов с почечно-
клеточным раком стадий T1N0M0 и T2N0M0. Приведены физикальные, лабораторные …

Quantitative accuracy of slow-rotating dynamic SPECT

J Zeintl, AH Vija, A Yahil, J Hornegger… - 2009 IEEE Nuclear …, 2009 - ieeexplore.ieee.org
We investigated biases in time-activity measurements relevant for quantitative dynamic
SPECT/CT imaging when slow-rotating dual-headed gamma camera systems in …

Определение экспрессии мРНК маммаглобина как маркера раннего рака молочной железы

ВК Боженко, ВА Солодкий, НВ Харченко… - Вестник Российского …, 2013 - cyberleninka.ru
Было исследовано 114 образцов ткани молочной железы, из них 57 образцов рака
молочной железы (РМЖ) I—IV стадии и 57 образцов неизмененной ткани молочной …